This page shows the latest PNH news and features for those working in and with pharma, biotech and healthcare.
Victor Bultó, president US, Novartis, described the approval as an "extraordinary moment” for the PNH community. ... This new, effective oral medicine may mean that patients can reset their expectations of living with PNH,” he said.
Roche has announced positive results from its phase 3 study of crovalimab in patients with paroxysmal nocturnal haemoglobinuria (PNH), a rare and life threatening blood condition. ... for PNH patients switching from currently approved C5 inhibitors to
PNH is a rare, chronic and life-threatening blood disease, affecting approximately ten to 20 people per million worldwide. ... part of the biology responsible for PNH while offering an oral monotherapy option.
with paroxysmal nocturnal haemoglobinuria (PNH) experiencing residual anaemia despite prior treatment with anti-C5s. ... part of the biology responsible for PNH while offering an oral monotherapy option.
PNH is a rare, acquired, life-threatening disease of the blood characterised by intravascular haemolytic anaemia, bone marrow failure and thromboembolic episodes, and is associated with a significant increase in mortality, ... with PNH in nearly 50
PNH is a rare blood condition where red blood cells are destroyed and can result in blood clots and impaired bone marrow function. ... who are clinically stable after treatment with Alexion’s older PNH drug Soliris (eculizumab).
More from news
Approximately 4 fully matching, plus 29 partially matching documents found.
It is a next- generation follow-on to Soliris, Alexion’s current PNH blockbuster – also a humanised monoclonal antibody – with more convenient dosing. ... Ultomiris received approval as an Orphan Drug from the FDA for adult patients with PNH in
Alexion is bracing for the patent expiry of its blockbuster Soliris (eculizumab), used to treat paroxysmal nocturnal haemoglobinuria (PNH) and myasthenia gravis, which hit revenues of around $3bn in 2018. ... The follow-up, Ultomiris ALXN1210, is a second
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
No results were found
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...